Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

By Jean-Marie Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Berdelou, A. Varga, R. Bahleda, A. Hollebecque and 14 more. European Journal of Cancer, 2016

1,994 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/04aa7b900d62c43a63cb3b040bb29e8c487dcf1c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Wolchok
2. C. Robert
3. R. Sherry

In Oncology

1. J. Wolchok
2. C. Robert
3. M. Lacouture
4. R. Sherry
5. M. Postow

Citations in the corpus

• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “threatening, or even fatal (grade 3, 4, or 5) events is higher after ipilimumab (10–40%) compared to nivolumab or pembrolizumab (<5%) [17, 19].”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “autoimmune causes as well as with a peripheral smear, reticulocyte count and assessment for hemolysis [88].”
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “Guidelines, literature, and knowledge on contraindications and adverse effects are developing, including on the management of patients receiving immune checkpoint therapy with adverse events (see Recommendation A2).(2) All patients should have received molecular testing (other organizations recommen”
• PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, methodology): “Currently, the two classes of immunotherapy that have been FDA approved for clinical use are (1) inhibitors of either the programmed death receptor 1 (PD-1) or its ligand (PD-L1), or (2) cytotoxic Tcell lymphocyte-associated protein 4 (CTLA-4) (Michot et al., 2016).”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “Further studies are needed to investigate whether a patient’s biologic profile predisposes to the occurrence of irAEs.(137) Possible treatment-specific risks for increased irAEs include dose of therapy, individual checkpoint inhibitor (CTLA-4 v PD-1), and combination checkpoint blockade.”